NCT06620913

Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 232 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Paraneoplastic neurological syndromes are rare syndromes caused by the remote effects of cancer. They have an immune-mediated pathogenesis, yet the underlying mechanisms are not fully elucidated. CV2/Collapsin response-mediator protein 5 (CRMP5)-IgG paraneoplastic neurological syndrome is characterized by heterogeneous clinical presentations, affecting both central and peripheral nervous system, and the most frequently associate tumor is small cell lung carcinoma. Central nervous system involvement along with CSF and neuroimaging findings have not been fully described in the literature in CV2/CRMP5 patients. Unraveling the complexities of CV2/CRMP5 paraneoplastic neurological syndrome is critical to improve diagnosis, treatment, and patients' care. Our intention is to perform a comprehensive analysis of the clinical characteristics and instrumental investigations of a large cohort of CV2/CRMP5 patients.

Conditions

• CV2 Autoimmunity

Interventions

Type	Name	Description
OTHER	Description of clinical, immunological and tumor features of patients harboring CV2 Abs	This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-09-01
• Completion: 2026-05-01
• First posted: 2024-10-01
• Last updated: 2024-10-01

Locations

1 site across 1 country: France